Published in J Clin Invest on August 01, 1992
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Vaccination against typhoid fever: present status. Bull World Health Organ (1994) 1.52
Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun (2002) 1.47
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect Immun (1997) 1.43
In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect Immun (2000) 1.32
Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect Immun (1996) 1.32
Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response. Infect Immun (1999) 1.30
Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity. Clin Diagn Lab Immunol (1997) 1.23
Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun (2004) 1.17
Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun (1996) 1.17
Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA. Infect Immun (1999) 1.13
A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun (2008) 1.12
Salmonella typhi stimulation of human intestinal epithelial cells induces secretion of epithelial cell-derived interleukin-6. Infect Immun (1997) 1.12
Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccines. Infect Immun (2000) 1.05
Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi. Infect Immun (2006) 1.02
Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun (2001) 1.01
Complex adaptive immunity to enteric fevers in humans: lessons learned and the path forward. Front Immunol (2014) 0.99
Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters. Infect Immun (2005) 0.94
Live attenuated vaccines for invasive Salmonella infections. Vaccine (2015) 0.86
Typhoid fever & vaccine development: a partially answered question. Indian J Med Res (2012) 0.85
Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice. PLoS One (2012) 0.83
In vitro Intestinal Mucosal Epithelial Responses to Wild-Type Salmonella Typhi and Attenuated Typhoid Vaccines. Front Immunol (2013) 0.81
Recombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag. Viruses (2013) 0.80
Regulation of Vi capsular polysaccharide synthesis in Salmonella enterica serotype Typhi. J Infect Dev Ctries (2008) 0.80
Attenuating gene expression (AGE) for vaccine development. Virulence (2013) 0.78
Salmonella Typhimurium TTSS-2 deficient mig-14 mutant shows attenuation in immunocompromised mice and offers protection against wild-type Salmonella Typhimurium infection. BMC Microbiol (2013) 0.75
Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (1981) 19.90
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
A two-component regulatory system (phoP phoQ) controls Salmonella typhimurium virulence. Proc Natl Acad Sci U S A (1989) 9.79
Induction of Salmonella stress proteins upon infection of macrophages. Science (1990) 5.30
Typhoid fever: pathogenesis and immunologic control. N Engl J Med (1970) 4.95
Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages. J Bacteriol (1990) 4.87
Intracellular survival of wild-type Salmonella typhimurium and macrophage-sensitive mutants in diverse populations of macrophages. Infect Immun (1989) 4.63
Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun (1987) 4.28
The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol (1991) 3.52
Characterization of aromatic- and purine-dependent Salmonella typhimurium: attention, persistence, and ability to induce protective immunity in BALB/c mice. Infect Immun (1988) 3.44
The effects of biochemical mutation on the virulence of Bacterium typhosum: the virulence of mutants. Br J Exp Pathol (1950) 3.35
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
GENETIC MAPPING OF VI AND SOMATIC ANTIGENIC DETERMINANTS IN SALMONELLA. J Bacteriol (1965) 2.90
Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med (1987) 2.83
Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am J Vet Res (1984) 2.60
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Identification of protein X of Escherichia coli as the recA+/tif+ gene product. Mol Gen Genet (1977) 2.36
Virulence and vaccine potential of phoP mutants of Salmonella typhimurium. Microb Pathog (1989) 2.32
Isolation of Vi antigen and a simple method for its measurement. Appl Microbiol (1972) 2.20
Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect Immun (1981) 2.15
In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. Antimicrob Agents Chemother (1985) 2.07
Construction of delta aroA his delta pur strains of Salmonella typhi. J Bacteriol (1988) 2.03
Oral Salmonella: malaria circumsporozoite recombinants induce specific CD8+ cytotoxic T cells. J Exp Med (1990) 1.93
Auxotrophic Salmonella typhi as live vaccine. Vaccine (1988) 1.87
A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun (1988) 1.86
The ability of Salmonella typhimurium to produce the siderophore enterobactin is not a virulence factor in mouse typhoid. Infect Immun (1985) 1.77
Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immun (1984) 1.70
Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes. J Infect Dis (1988) 1.69
Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun (1990) 1.64
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Progress in vaccines against typhoid fever. Rev Infect Dis (1989) 1.49
Cellular immunity induced by avirulent Salmonella in LPS-defective C3H/HeJ mice. J Immunol (1984) 1.48
Effect of a purA mutation on efficacy of Salmonella live-vaccine vectors. Infect Immun (1989) 1.43
Genetic determination of bacterial virulence, with special reference to Salmonella. Curr Top Microbiol Immunol (1986) 1.34
Excretion of flagellin by a short-flagella mutant of Salmonella typhimurium. J Bacteriol (1983) 1.21
Attenuated, streptomycin-dependent Salmonella typhi oral vaccine: potential deleterious effects of lyophilization. J Infect Dis (1976) 1.15
Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J Infect Dis (1991) 1.14
Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine (1991) 1.10
Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J Clin Microbiol (1987) 1.08
Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine (1991) 1.06
The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. J Clin Invest (1969) 1.05
Bacteriophage P22 as a vehicle for transducing cosmid gene banks between smooth strains of Salmonella typhimurium: use in identifying a role for aroD in attenuating virulent Salmonella strains. Mol Gen Genet (1989) 1.04
In vitro characterization of Salmonella typhi mutant strains for live oral vaccines. Vaccine (1990) 1.00
Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella. Proc Natl Acad Sci U S A (1989) 0.94
Vaccination of calves against Salmonella dublin with aromatic-dependent Salmonella typhimurium. Am J Vet Res (1984) 0.91
Studies on infection and immunity in experimental typhoid fever. VI. Response of chimpanzees to endotoxin and the effect of tolerance on resistance to oral challenge. J Infect Dis (1965) 0.79
The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol (1975) 19.91
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (1988) 4.12
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Clinical features and an epidemiological study of Vibrio vulnificus infections. J Infect Dis (1984) 3.69
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Duration of infection-derived immunity to cholera. J Infect Dis (1981) 3.60
Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. J Gen Microbiol (1976) 3.54
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Comparison of assay techniques for beta-lactamase activity. Anal Biochem (1973) 2.96
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
Experimental human infections with Giardia lamblia. J Infect Dis (1987) 2.42
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg (2000) 2.39
Enteroaggregative Escherichia coli elaborate a heat-stable enterotoxin demonstrable in an in vitro rabbit intestinal model. J Clin Invest (1991) 2.35
Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am J Epidemiol (1991) 2.34
Morphological studies on fimbriae expressed by Vibrio cholerae 01. Microb Pathog (1988) 2.33
Reduction of transmission of shigellosis by control of houseflies (Musca domestica) Lancet (1991) 2.30
Immunity to enterotoxigenic Escherichia coli. Infect Immun (1979) 2.30
Enteroaggregative Escherichia coli heat-stable enterotoxin 1 represents another subfamily of E. coli heat-stable toxin. Proc Natl Acad Sci U S A (1993) 2.28
Hemagglutination and colonization factors in enterotoxigenic and enteropathogenic Escherichia coli that cause diarrhea. J Infect Dis (1980) 2.26
The capsule and O antigen in Vibrio cholerae O139 Bengal are associated with a genetic region not present in Vibrio cholerae O1. Infect Immun (1995) 2.25
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers. Infect Immun (1992) 2.23
Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med (1998) 2.20
Typhoid fever vaccines. Vaccine (1999) 2.18
Illness caused by Vibrio damsela and Vibrio hollisae. Lancet (1982) 2.17
Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans. J Infect Dis (1996) 2.17
Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet (1987) 2.17
Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. J Infect Dis (1982) 2.14
The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil. J Infect Dis (1982) 2.13
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis (1995) 2.10
Human infection with Ascaris lumbricoides is associated with suppression of the interleukin-2 response to recombinant cholera toxin B subunit following vaccination with the live oral cholera vaccine CVD 103-HgR. Infect Immun (2001) 2.09
Viable but non-culturable Vibrio cholerae O1 revert to a cultivable state in the human intestine. World J Microbiol Biotechnol (1996) 2.05
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
Cytokine production patterns and lymphoproliferative responses in volunteers orally immunized with attenuated vaccine strains of Salmonella typhi. J Infect Dis (1994) 2.03
Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis (2000) 2.02
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01